Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of  LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with 

fusion non-small cell lung cancers (NSCLC).

To date, the LIBRETTO-001 trial has treated 105 patients across NSCLCs and shows a 68% response rate, with some cases of complete response to selpercatinib.

Drilon says, this trial serves an unmet need in NSCLC, since there is no approved targeted therapy for 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial